Teladoc Health Future Growth
Future criteria checks 0/6
Teladoc Health is forecast to grow earnings and revenue by 81.7% and 0.7% per annum respectively. EPS is expected to grow by 85.6% per annum. Return on equity is forecast to be -10.9% in 3 years.
Key information
81.7%
Earnings growth rate
85.6%
EPS growth rate
| Healthcare Services earnings growth | 31.9% |
| Revenue growth rate | 0.7% |
| Future return on equity | -10.9% |
| Analyst coverage | Good |
| Last updated | 16 Dec 2024 |
Recent future growth updates
Recent updates
Teladoc: Attractive Valuation, But The Narrative Stalls
Dec 20Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)
Nov 27Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement
Nov 26
Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Nov 02Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 23Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition
Oct 13Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Sep 18Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive
Sep 15Teladoc: Prospects Are Ready For Better Health
Sep 04Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)
Aug 01Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)
Jul 22Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jul 17Teladoc Health: Weight Loss Management Could Help
Jul 01Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?
Jun 04Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards
May 31Teladoc: Huge Execution Problem
Apr 27Teladoc: Improving Business Trends (Rating Upgrade)
Apr 17Teladoc: Management Has A Lot To Prove To Gain Investor Confidence
Mar 25Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues
Mar 10Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation
Feb 21Teladoc Health: Weight Management Rescue
Jan 21Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt
Jan 15When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Dec 12Teladoc Q3: Getting Stronger (Rating Upgrade)
Nov 29Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price
Nov 22Teladoc Was Obliterated
Oct 25Is Teladoc Health (NYSE:TDOC) A Risky Investment?
Oct 11Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)
Oct 02Teladoc Stock: A Hold Amid New Covid Wave
Sep 14Teladoc's Technical Decline Hints At A Buying Opportunity
Aug 28Is There An Opportunity With Teladoc Health, Inc.'s (NYSE:TDOC) 44% Undervaluation?
Aug 18Buy Teladoc: AI Will Likely Spur Healthcare Deflation
Aug 16Teladoc's Future: Virtual Healthcare, AI, And Valuation
Jul 28Teladoc And Microsoft's Expanded Strategic Partnership Is A Powerful AI Combo
Jul 21The Big Trends: New Frontiers in Healthcare
Jul 13
When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?
Jul 10Teladoc Health: Likely To Remain Out Of Favor
Jun 26Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors
Jun 25Here's Why Teladoc Health (NYSE:TDOC) Can Afford Some Debt
May 25Teladoc: BetterHelp Segment Margins Are Key
May 23Are Investors Undervaluing Teladoc Health, Inc. (NYSE:TDOC) By 20%?
May 06Is It Too Late To Consider Buying Teladoc Health, Inc. (NYSE:TDOC)?
Mar 10Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2,590 | -145 | 241 | 364 | 19 |
| 12/31/2025 | 2,542 | -154 | 214 | 344 | 25 |
| 12/31/2024 | 2,569 | -988 | 176 | 308 | 25 |
| 9/30/2024 | 2,590 | -982 | 207 | 338 | N/A |
| 6/30/2024 | 2,609 | -1,006 | 196 | 333 | N/A |
| 3/31/2024 | 2,619 | -233 | 200 | 346 | N/A |
| 12/31/2023 | 2,602 | -220 | 194 | 350 | N/A |
| 9/30/2023 | 2,580 | -4,002 | 112 | 285 | N/A |
| 6/30/2023 | 2,531 | -4,018 | 64 | 243 | N/A |
| 3/31/2023 | 2,471 | -7,054 | 47 | 234 | N/A |
| 12/31/2022 | 2,407 | -13,660 | 17 | 189 | N/A |
| 9/30/2022 | 2,323 | -9,860 | 65 | 207 | N/A |
| 6/30/2022 | 2,234 | -9,871 | 107 | 221 | N/A |
| 3/31/2022 | 2,144 | -6,904 | 99 | 180 | N/A |
| 12/31/2021 | 2,033 | -429 | 130 | 194 | N/A |
| 9/30/2021 | 1,862 | -812 | -54 | -4 | N/A |
| 6/30/2021 | 1,629 | -763 | -92 | -49 | N/A |
| 3/31/2021 | 1,367 | -655 | -102 | -65 | N/A |
| 12/31/2020 | 1,094 | -485 | -80 | -54 | N/A |
| 9/30/2020 | 867 | -110 | 59 | 80 | N/A |
| 6/30/2020 | 716 | -95 | 46 | 61 | N/A |
| 3/31/2020 | 606 | -98 | 19 | 31 | N/A |
| 12/31/2019 | 553 | -99 | 19 | 30 | N/A |
| 9/30/2019 | 520 | -105 | 4 | 14 | N/A |
| 6/30/2019 | 493 | -108 | 2 | 11 | N/A |
| 3/31/2019 | 457 | -103 | -8 | 1 | N/A |
| 12/31/2018 | 418 | -97 | -13 | -5 | N/A |
| 9/30/2018 | 372 | -117 | -22 | -15 | N/A |
| 6/30/2018 | 330 | -125 | N/A | -37 | N/A |
| 3/31/2018 | 280 | -115 | N/A | -36 | N/A |
| 12/31/2017 | 233 | -107 | N/A | -34 | N/A |
| 9/30/2017 | 194 | -77 | N/A | -35 | N/A |
| 6/30/2017 | 157 | -75 | N/A | -38 | N/A |
| 3/31/2017 | 139 | -75 | N/A | -47 | N/A |
| 12/31/2016 | 123 | -74 | N/A | -52 | N/A |
| 9/30/2016 | 108 | -75 | N/A | -57 | N/A |
| 6/30/2016 | 96 | -58 | N/A | -59 | N/A |
| 3/31/2016 | 88 | -61 | N/A | -54 | N/A |
| 12/31/2015 | 77 | -58 | N/A | -47 | N/A |
| 9/30/2015 | 68 | -50 | N/A | -39 | N/A |
| 6/30/2015 | 59 | -42 | N/A | -24 | N/A |
| 3/31/2015 | 51 | -29 | N/A | -19 | N/A |
| 12/31/2014 | 44 | -20 | N/A | -11 | N/A |
| 12/31/2013 | 20 | -10 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TDOC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TDOC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TDOC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TDOC's revenue (0.7% per year) is forecast to grow slower than the US market (9.1% per year).
High Growth Revenue: TDOC's revenue (0.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TDOC is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Teladoc Health, Inc. is covered by 44 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Vikram Kesavabhotla | Baird |
| Matthew Gillmor | Baird |